- life sciences/pharma sector
-
2nd Annual Drug Repositioning and Pipeline Enhancement
Scientific and Strategic Approaches for Repositioning and Building a Robust Pipeline Through Innovation, Science, and Commercial Strategy
Event Date: 17-18 Sep 2009
Location: Ritz Carlton, Philadelphia, PA, USA
- key conference speakers
-
Sarma P. Duddu, PhD General Manager and Vice President of Drug Delivery Technologies , Cephalon & CIMA Labs Sesha Neervannan, PhD Vice President, Pharmaceutical Development, Allergan, Inc. Bruce Pratt, PhD Vice President, Science Development, Genzyme Corporation Linda A. Egger PhD Director, Scientific Liaison, External Scientific Affairs - Oncology Licensing , Merck and Co. Yetunde Taiwo, PhD Director, Global External Research & Development, Eli Lilly & Co.
- key conference topics
-
- External Innovation Partnership Strategies
- Effective Drug Delivery Tools and Key Safety Considerations
- Opportunities and Challenges for Applying Controlled Release Drug Delivery to Improve Efficacy and Tolerability
- Expanding Patient Potential and Indications For Existing Compounds
- Enhancing Products Through Strategic IP Protection, Collaborations and Reformulation
- conference focus
-
Due to recent changes in the industry, pharmaceutical companies are scrambling for novel solutions to extend and accelerate dr Due to recent changes in the industry, pharmaceutical companies are scrambling for novel solutions to extend and accelerate drug exclusivity. Drug reformulation and repositioning offers the pharma industry’s solution for falling research and development productivity and weakening product pipelines. Successfully repositioned drugs have enabled innovative companies to adopt lower risk strategies to optimize product pipelines. By attending this conference attendees will gain a better understanding on how to optimize the company pipeline and how to implement successful technologies and business models that will enhance their clinical and commercial output. They will also learn strategies for selecting late stage and abandoned compounds and refueling the pipeline by reformulation, indication expansion, IP protection, and in/out licensing.